info@trade-jp.net
menu
News / Blog
New Year holidays Schedule
Catalog
Camostat Mesilate tablets 100 mg 100 tbaltes (Foipan)
Product Code :
Availability : 10
USD 39.90
General information on Camostat Mesilate tablets 100 mg
Package details: 100 tablets
Manufacturer: Towa / Sawai / Nichiiko pharmaceutical co. ltd, Japan
Active ingredient: camostat mesilate (chemical formula C20H22N4O5)
Medical effect: Camostat tablets are effective for the following procedures:
- inhibits digestive enzymes in pancreatic fluid, suppressing abnormal increases of the enzyme activity,
- ameliorates symptoms by inhibiting trypsin in digestive juice,
- it is effective for some specific cancer forms,
- it is effective for some specific virus infections.
- some efects are reported for SARS and Coronavirus (see link below).
Contraindications and precautions: do not use for pregnant or breastfeeding women. If an allergic reaction occurs, stop using the medication and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.
Dosage and administration of Japanese Camostat tablets 100 mg.
For chronic pancreatitis take two tablets three times a day.
For postoperative reflux esophagitis you should take one tablet 3 times a day.
This dosage may adjust the dosage according to age and symptoms.
How effective are Japanese Camostat tablets 100 mg?
This Japanese medicine is an effective proteolytic enzyme inhibitor. Camostat tablets inhibit digestive enzymes in pancreatic fluid in short time and effectively suppresses all abnormal increases and fluctuations of the enzyme activity. Camostat tablets from Japan also ameliorates symptoms by inhibiting trypsin in digestive juice. Due o its vast effect this medicine is used to treat different types of cancer and it is also acknowledged to be effective for a vast range of viral diseases. An in vitro study shows that Camostat reduces significantly the infection of Calu-3 lung cells by SARS-CoV-2, the virus responsible for COVID-19 (Hoffman, Markus (2020-03-05). "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor").
